Tag Archives: 340B program
The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities For Congress
Previous assessments of the 340B program have largely focused on cherry-picked participants. But DSH hospitals that participate in 340B are quite diverse. A priority for policymakers should be more systematic and timely data on participating DSH hospitals’ 340B revenue and safety-net services.
October 10, 2017
If President Trump truly intends to control drug costs, fixing drug pricing formulas and enhancing existing penalties could reduce costs for both public and private payers.
March 31, 2017
Policies giving federal and state governments authority to set drug prices or limit price increases could have the unintended consequence of reducing the incentive to develop more effective drugs. However, certain regulatory reforms can address these concerns and encourage more robust...
July 11, 2016
In a previous blog, I described “the coming storm” I anticipated would develop around the 340B drug discount program. With the October 27 comment window steadily approaching, let’s take a look at what the rule says and what it could mean for interested stakeholders.
October 20, 2015